ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Sponsor: Alnylam Pharmaceuticals
Listed as NCT02319005, this PHASE3 trial focuses on Amyloid Neuropathies and Amyloid Neuropathies, Familial and remains completed. Sponsored by Alnylam Pharmaceuticals, it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jun 2017 — Dec 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alnylam Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .